RegentAtlantic Capital’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $7.62M | Buy |
107,166
+3,092
| +3% | +$224K | 0.23% | 76 |
|
|
2022
Q2 | $8.01M | Buy |
104,074
+2,939
| +3% | +$224K | 0.26% | 69 |
|
|
2022
Q1 | $7.39M | Buy |
101,135
+18,453
| +22% | +$1.24M | 0.21% | 85 |
|
|
2021
Q4 | $5.16M | Sell |
82,682
-12,407
| -13% | -$728K | 0.14% | 120 |
|
|
2021
Q3 | $5.63M | Buy |
95,089
+11,885
| +14% | +$783K | 0.17% | 101 |
|
|
2021
Q2 | $5.56M | Buy |
83,204
+4,889
| +6% | +$319K | 0.17% | 106 |
|
|
2021
Q1 | $4.94M | Buy |
78,315
+6,538
| +9% | +$407K | 0.17% | 107 |
|
|
2020
Q4 | $4.45M | Buy |
71,777
+146
| +0.2% | +$8.98K | 0.18% | 105 |
|
|
2020
Q3 | $4.32M | Sell |
71,631
-3,464
| -5% | -$208K | 0.19% | 101 |
|
|
2020
Q2 | $4.42M | Buy |
75,095
+11,626
| +18% | +$695K | 0.25% | 88 |
|
|
2020
Q1 | $3.54M | Buy |
63,469
+14,785
| +30% | +$904K | 0.28% | 86 |
|
|
2019
Q4 | $3.13M | Buy |
48,684
+27,047
| +125% | +$1.55M | 0.19% | 126 |
|
|
2019
Q3 | $1.1M | Buy |
21,637
+5,044
| +30% | +$237K | 0.07% | 217 |
|
|
2019
Q2 | $752K | Sell |
16,593
-1,522
| -8% | -$70.9K | 0.05% | 254 |
|
|
2019
Q1 | $864K | Sell |
18,115
-481
| -3% | -$24K | 0.06% | 234 |
|
|
2018
Q4 | $967K | Sell |
18,596
-640
| -3% | -$34.4K | 0.08% | 216 |
|
|
2018
Q3 | $1.19M | Buy |
19,236
+4,313
| +29% | +$256K | 0.09% | 207 |
|
|
2018
Q2 | $826K | Sell |
14,923
-350
| -2% | -$18.9K | 0.07% | 234 |
|
|
2018
Q1 | $966K | Sell |
15,273
-436
| -3% | -$28K | 0.08% | 214 |
|
|
2017
Q4 | $963K | Buy |
15,709
+623
| +4% | +$39K | 0.08% | 216 |
|
|
2017
Q3 | $962K | Buy |
15,086
+522
| +4% | +$30.5K | 0.08% | 208 |
|
|
2017
Q2 | $812K | Buy |
14,564
+745
| +5% | +$40.5K | 0.07% | 221 |
|
|
2017
Q1 | $751K | Sell |
13,819
-102
| -0.7% | -$5.59K | 0.07% | 229 |
|
|
2016
Q4 | $814K | Buy |
13,921
+723
| +5% | +$39.5K | 0.08% | 219 |
|
|
2016
Q3 | $712K | Buy |
13,198
+437
| +3% | +$28.1K | 0.07% | 232 |
|
|
2016
Q2 | $939K | Sell |
12,761
-368
| -3% | -$26K | 0.09% | 194 |
|
|
2016
Q1 | $839K | Sell |
13,129
-436
| -3% | -$27.5K | 0.09% | 181 |
|
|
2015
Q4 | $933K | Buy |
13,565
+2,491
| +22% | +$165K | 0.1% | 192 |
|
|
2015
Q3 | $656K | Sell |
11,074
-1,113
| -9% | -$70.6K | 0.06% | 229 |
|
|
2015
Q2 | $811K | Buy |
12,187
+255
| +2% | +$16.8K | 0.07% | 203 |
|
|
2015
Q1 | $770K | Sell |
11,932
-275
| -2% | -$17.2K | 0.07% | 212 |
|
|
2014
Q4 | $721K | Sell |
12,207
-361
| -3% | -$20.4K | 0.06% | 220 |
|
|
2014
Q3 | $643K | Buy |
12,568
+136
| +1% | +$6.79K | 0.06% | 221 |
|
|
2014
Q2 | $603K | Sell |
12,432
-848
| -6% | -$41.8K | 0.06% | 234 |
|
|
2014
Q1 | $690K | Sell |
13,280
-312
| -2% | -$16.6K | 0.07% | 213 |
|
|
2013
Q4 | $722K | Sell |
13,592
-29
| -0.2% | -$1.48K | 0.07% | 210 |
|
|
2013
Q3 | $630K | Buy |
13,621
+1,757
| +15% | +$77.1K | 0.07% | 208 |
|
|
2013
Q2 | $526K | Buy |
+11,864
| New | +$515K | 0.06% | 218 |
|
Other funds holding BMY
RegentAtlantic Capital's BMY Position: Q3 2022 in Review
RegentAtlantic Capital increased its Bristol-Myers Squibb (BMY) stake by 3% in Q3 2022, buying an estimated $224K and bringing the position to 107,166 shares worth $7.62M. The position accounts for 0.23% of the portfolio, ranked #76.
RegentAtlantic Capital first reported a position in BMY in Q2 2013 and has held it in 38 quarters since. The position peaked at $8.01M in Q2 2022. 2,469 funds tracked by Wall St. Rank hold BMY as of Q3 2022.
- RegentAtlantic Capital held 107,166 shares of Bristol-Myers Squibb worth $7.62M as of Q3 2022.
- RegentAtlantic Capital bought 3,092 Bristol-Myers Squibb shares in Q3 2022, an estimated $224K.
- Bristol-Myers Squibb made up 0.23% of RegentAtlantic Capital's portfolio in Q3 2022, its #76 holding.
- RegentAtlantic Capital first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 38 quarters since.
- RegentAtlantic Capital's Bristol-Myers Squibb position peaked at $8.01M in Q2 2022.
- 2,469 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2022.
Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.